MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Amgen Inc

Closed

SectorHealthcare

305.92 -0.26

Overview

Share price change

24h

Current

Min

300.07

Max

306.68

Key metrics

By Trading Economics

Income

-2.2B

627M

Sales

586M

9.1B

P/E

Sector Avg

41.156

63.778

EPS

5.31

Dividend yield

3.06

Profit margin

6.901

Employees

28,000

EBITDA

-517M

2.9B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+8.31% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.06%

2.39%

Next Earnings

1 maj 2025

Next Dividend date

6 cze 2025

Next Ex Dividend date

16 maj 2025

Market Stats

By TradingEconomics

Market Cap

14B

167B

Previous open

306.18

Previous close

305.92

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Amgen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 lut 2025, 21:29 UTC

Earnings

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 paź 2024, 20:18 UTC

Earnings

Amgen Posts Higher 3Q Sales on Strong Demand

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 lut 2025, 21:02 UTC

Earnings

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Adj EPS $5.31 >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Rev $9.1B >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q EPS $1.16 >AMGN

4 lut 2025, 21:01 UTC

Earnings

Amgen 4Q Net $627M >AMGN

28 sty 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 gru 2024, 07:00 UTC

Earnings

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 gru 2024, 15:04 UTC

Top News

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 gru 2024, 14:53 UTC

Top News

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 lis 2024, 12:00 UTC

Top News

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 lis 2024, 12:34 UTC

Top News

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 lis 2024, 12:00 UTC

Top News

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 paź 2024, 20:02 UTC

Earnings

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 paź 2024, 20:02 UTC

Earnings

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 paź 2024, 20:02 UTC

Earnings

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 paź 2024, 20:02 UTC

Earnings

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 paź 2024, 20:02 UTC

Earnings

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 paź 2024, 20:01 UTC

Earnings

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 paź 2024, 20:01 UTC

Earnings

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 paź 2024, 20:01 UTC

Earnings

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

8.31% upside

12 Months Forecast

Average 332.43 USD  8.31%

High 389 USD

Low 280 USD

Based on 18 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

11

Buy

6

Hold

1

Sell

Technical Score

By Trading Central

305.71 / 315.18Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.